Search PubMed⌕ Search

Biomedical subjects

A Oohira

Publications and source records attributed to A Oohira.

At least 19 recordsLinked to original sources
PubMed1999

[Ocular blood flow defect in gaze-evoked amaurosis].

PURPOSE: To investigate the mechanism of gaze-evoked amaurosis. CASE: A patient with an optic nerve tumor presented gaze-evoked amaurosis. A large central scotoma and constricted visual field were detected after shifting the gaze laterally. However, the patient did not notice this change until his fellow eye was occluded. Computed tomography/magnetic resonance imaging (CT/MRI) demonstrated a tubularly enlarged optic nerve extending for 1 cm from the eye ball, and the condition was judged to be optic nerve sheath meningioma. He underwent fluorescein fundus angiography twice, once during straight gaze and again during lateral gaze. RESULTS: Manifestly decreased blood flow in the central retinal artery and filling defect in the optic nerve head were seen during lateral gaze. CONCLUSION: Forced lateral gaze may have increased the intra-optic nerve pressure at the optic nerve head and decreased the blood flow of the central retinal artery and peripapillary choroidal flow irrigating the optic nerve head.

Blindness↗
PubMed1998

Coordinate expression of L1 and 6B4 proteoglycan/phosphacan is correlated with the migration of mesencephalic dopaminergic neurons in mice.

Mesencephalic dopaminergic (DA) neurons of mice are generated from embryonic day 10 to 12 (E10-12) in the ventricular zone of the mesencephalon. They first migrate toward the ventral mesencephalon, and then turn laterally, or tangentially, in the basal part of the mesencephalon. With immunohistochemical analysis of E10-E15 ICR mice, we found that cell adhesion molecule L1 was transiently expressed on the median part of tangential fibers coincident with the lateral migration of DA neurons from E11 to E13, when neurons move along the tangential fibers toward their final destinations: the reticular formation, the substantia nigra pars compact, and the ventral tegmental area. While L1 expression was not observed in DA neurons, they expressed a chondroitin sulfate proteoglycan, 6B4 proteoglycan/phosphacan, which has been shown to bind to L1/Ng-CAM in vitro. These results suggest that the heterophilic interaction between 6B4 proteoglycan on the neurons and L1 on the fibers is involved in the lateral migration of mesencephalic DA neurons in mice.

Animals↗
PubMed1998

Occurrence of a N-terminal proteolytic fragment of neurocan, not a C-terminal half, in a perineuronal net in the adult rat cerebrum.

Neurocan is a nervous tissue-unique chondroitin sulfate proteoglycan (CSPG) whose expression and proteolytic cleavage are developmentally regulated. In the adult rat brain, neurocan is completely cleaved into some proteoglycan fragments including the C-terminal half known as neurocan-C and a N-terminal fragment with a 130 kDa core glycoprotein (neurocan-130). We describe here the differential distribution of these two neurocan-derived CSPGs in the adult rat cerebrum and the occurrence of neurocan-130 as a new member of a perineuronal net-constituting molecule. At the light microscopic level, neurocan-130 exhibited pericellular localization around a subset of neurons in addition to diffuse distribution in the neuropil. In contrast, neurocan-C was distributed only diffusely in the neuropil. Double staining with anti-neurocan-130 and anti-synaptophysin antibodies suggested that neurocan-130 was localized in the vicinity of the synapses, but not at the synapses. Immunoelectron microscopy showed that neurocan-130 was mainly localized in the cytoplasm of glial cell processes, the so-called glial perineuronal net, encompassing the cell bodies of certain neurons. The presence of neurocan-130 in a limited number of glial cells may reflect some functional heterogeneity of the glia.

Age Factors↗
PubMed1998

Two types of brain chondroitin sulfate proteoglycan: their distribution and possible functions in the rat embryo.

The distribution of neurocan-like and 6B4 proteoglycan-like immunoreactivities in the rat embryo was investigated from gestational days 10.5-15.5 with monoclonal antibody 1G2 or 6B4 that immunoreacted with neurocan and 6B4 proteoglycan, respectively. In the brain region, the leptomeningeal layer in the myelencephalon, metencephalon, diencephalon or telencephalon was first stained with monoclonal antibody 1G2 at embryonic day 12.5. In the spinal cord, monoclonal antibody 1G2 stained the regions corresponding to the boundary caps (designated the boundary caps) after embryonic day 11.5 and the roof plate after embryonic day 12.5. The intensity of staining in the boundary caps reached a maximum at embryonic day 13.5, at around the time when the axons from the dorsal root ganglia reach this region. However, the points of contact of the axons with the boundary caps were hardly stained. By contrast, the roof plate was most strongly and widely stained at embryonic day 14.5, at around the time when the axons enter the spinal cord. Western blotting of preparations from the spinal cord that included the boundary caps revealed the presence of neurocan in this region. Thus, it is likely that neurocan serves as a barrier molecule to regulate the direction of axonal growth from the dorsal root ganglia. By contrast, in addition to staining of the future brain and spinal cord, monoclonal antibody 6B4 stained the trigeminal and sympathetic ganglia in the rat embryo on and after embryonic day 12.5, as well as the vestibular, facial and dorsal root ganglia after embryonic day 12.5. In studies in tissue culture, monoclonal antibody 6B4 prevented the inhibitory effects of 6B4 proteoglycan on the proliferation of PC12D cells. No immunostaining with monoclonal antibody 6B4 was observed in cells that had incorporated bromodeoxyuridine in vivo. Possible functions of 6B4 proteoglycan in the rat embryo are discussed.

Animals↗
PubMed1998

Cloning and chromosomal mapping of the human gene of neuroglycan C (NGC), a neural transmembrane chondroitin sulfate proteoglycan with an EGF module.

Neuroglycan C (NGC) is a 150 kDa transmembrane chondroitin sulfate proteoglycan with a 120 kDa core glycoprotein that was originally isolated from the developing rat brain. A rabbit antiserum, raised against a recombinant polypeptide representing a protein of the rat NGC core protein, recognized an NGC homolog in homogenates of brains of various vertebrates including humans. Because of the possible involvement of this proteoglycan in the etiology of a human neuronal disease, we cloned a complete coding sequence from a human brain cDNA library using a rat NGC cDNA as a probe. The predicted protein contains 539 amino acids and shows 86% homology with the rat counterpart. The domain structure characteristic of rat NGC was completely conserved in human NGC, which consisted of an N-terminal signal sequence, a chondroitin sulfate-attachment domain, an acidic amino acid cluster, an EGF-like domain, a transmembrane domain and a cytoplasmic tail. Northern blot analysis revealed that a single transcript of 2.4 kb was detectable in the brain, but not in other human tissues. By fluorescence in situ hybridization (FISH) analysis, the human NGC gene was assigned to the chromosomal 3p21.3 band, where the Sotos syndrome has been mapped. Involvement of the NGC gene in the etiology of the Sotos syndrome remains to be examined.

Amino Acid Sequence↗
PubMed1997

Immunohistochemical localization of neurocan and L1 in the formation of thalamocortical pathway of developing rats.

We used immunohistochemistry to examine possible molecular interactions between the subplate and growing thalamocortical axons in rat fetuses. In the cortical anlage of embryonic day 16 (E16), the subplate first appeared below the cortical plate. Among chondroitin sulfate proteoglycans, phosphacan was uniformly distributed throughout the cortical wall, whereas neurocan was localized only in the subplate at E16. Neural cell adhesion molecules, NCAM-H, TAG-1, and L1, were detected in the cortical anlage. Both cortical neurons and growing axons were diffusely immunopositive for NCAM-H, and TAG-1 immunoreactivity was found on immature neurons and cortical efferent axons but not on thalamocortical axons. L1 immunoreactivity was specifically localized on the growing thalamocortical axons. When the locations of neurocan and L1 were compared in the developing cortex, L1-bearing axons were found to extend to neurocan-immunopositive regions; neurocan immunoreactivity was intense in the subplate at E16, when small numbers of L1-immunoreactive thalamocortical axons began to invade the cortex. At E17, many L1-positive axons were observed in the subplate that expressed neurocan specifically. Double immunostaining showed that L1-positive axons and neurocan immunoreactivity overlapped in the subplate at E17. After E18, neurocan expression gradually extended to the lower part of the cortical plate; it extended to the entire cortex by E21, 1 day before birth. By E21, L1-bearing axons had invaded the lower part of the cortical plate. The present study demonstrated that the neurocan expression precedes growth of L1-bearing thalamocortical afferent fibers. Because neurocan can bind to L1 molecule in vitro, these results suggest that neurocan and L1 play some important roles in pathfinding of the thalamocortical afferent fibers during rat corticogenesis.

Animals↗
PubMed1997

Immunohistochemical localization of neurocan in the lower auditory nuclei of the dog.

Chondroitin sulfate proteoglycans are present at high levels in the lower auditory system of mammals. Axon terminals on the principal neurons in the superior olivary nuclei contain chondroitin 4- and 6-sulfate, while the broad extracellular matrix around axon terminals contains chondroitin sulfate D, a highly sulfated chondroitin sulfate rich in the disaccharide unit of GlcA(2S)beta1 --> 3GalNAc(6S), in the dog. In the present study, we investigated the immunohistochemical staining of neurocan, a brain-specific proteoglycan, in the lower auditory tract of the dog, including an analysis by immunoelectron microscopy. Immunolocalization of neurocan was conspicuous in the medial and lateral superior olivary nuclei and much less intense immunostaining was seen in the cochlear nucleus and posterior colliculus. No immunoreactivity were found in other nuclei. The immunostaining in the medial and lateral superior olivary nuclei was observed as perineuronal nets around large principal neurons at the light-microscopic level, while no immunostaining was observed in the upper segment of the medial superior olivary nucleus and the medial segment of the lateral superior olivary nucleus, in which medium-sized and small neurons were located. Immunoelectron microscopy revealed the reaction products of immunostaining on cell membranes of the perikarya of principal neurons and on cell membranes of presynaptic terminals which made axo-somatic synapses on the principal cells. No immunoreactivity was detected at synaptic junctions, in the extracellular matrix or within axon terminals. In the cochlear nucleus, immunoreactive perineuronal nets were found around a small number of neurons and immunoreactive nerve fibers were scattered in the anterior ventral cochlear nucleus. In the posterior colliculus, perineuronal nets, which were weakly immunostained, were sparsely distributed in the central nucleus. These results suggest that different locations of chondroitin sulfate proteoglycans, including neurocan, may be associated with focal sites composed of neuronal surface, terminal boutons and extracellular matrix in the lower auditory tract of the adult dog.

Animals↗
PubMed1997

Identification of monoclonal antibody At5 as a new member of HNK-1 antibody family: the reactivity with myelin-associated glycoprotein and with two brain-specific proteoglycans, phosphacan and neurocan.

Monoclonal antibody At5 was primarily developed against chordin, a notochord-specific antigen of Acipenseridae (sturgeon fishes). In higher vertebrates the antibody reacted mainly with neural tissue antigens. In this study we have shown that the specificity of monoclonal antibody At5 is similar to that of antibodies of HNK-1 family which react with two glycolipids and with several high molecular weight glycoconjugates of neural tissue. We have demonstrated by protein sequencing and immunoblotting that one of At5 target antigens of human brain is dMAG, a derivative of myelin-associated glycoprotein. In the preparations of At5 antigens proteoglycans phosphacan and neurocan were identified by immunoblotting with specific monoclonal antibodies 6B4 and 1G2, respectively. The distribution of At5 and 6B4 immunoreactivity was studied on sections of mixed oligoastrocytoma. Oligodendroglioma area of this tumor was intensely stained with both antibodies, whereas astrocytoma area did not exhibit any At5 or 6B4 immunoreactivity.

Amino Acid Sequence↗
PubMed1996

A membrane-bound heparan sulfate proteoglycan that is transiently expressed on growing axons in the rat brain.

Monoclonal antibodies were raised to membrane-bound proteoglycans derived from rat brain and three monoclonal antibodies that recognized a 200-kDa heparan sulfate proteoglycan (designated H5-PG) with a core glycoprotein of 140 kDa were obtained. The expression of H5-PG was spatially and temporally regulated in the central nervous system. In the cerebellar cortex, H5-PG was associated mainly with the actively growing parallel fibers of granule cells. The expression was abruptly down-regulated in parallel with the formation of synapses on dendrites of Purkinje cells. In the cerebral cortex, the proteoglycan was widely distributed throughout the cortex. The temporal pattern of expression was similar to that in the cerebellar cortex; the peak level of expression was observed during the period from postnatal days 0 to 20 when neuritogenesis and synaptogenesis occur most extensively in the rat cerebral cortex. H5-PG in the central nervous system disappeared prior to adulthood except in the olfactory bulb. High-level expression was recognized on the olfactory nerves and glomeruli, where the renewal of both axons and synapses is occurring constantly. The data suggest that H5-PG is a glycoconjugate on axonal surface that is involved in axonal outgrowth and/or synaptogenesis.

Animals↗
PubMed1996

Influence on visual function by a stereoscopic TV programme with binocular liquid crystal shutter and Hi-Vision TV display.

Influence on visual functions by field sequential stereoscopic Hi-Vision TV programme with liquid crystal shutter were investigated in 24 subjects. Ocular alignment, fusional amplitude, AC/A ratio, stereoacuity, accommodation and pupil size were measured before and after the visual load. Symptoms related to asthenopia were also examined. No significant difference were found, although two aged subjects showed large changes in a few of these functions. This type of 3-D display may not be hazardous to visual functions, although further study may be required for aged or visually handicapped people.

Accommodation, Ocular↗
PubMed1995

Neuroglycan C, a novel membrane-spanning chondroitin sulfate proteoglycan that is restricted to the brain.

Monoclonal antibodies were raised to membrane-bound proteoglycans derived from rat brain, and four monoclonal antibodies that recognized a 150-kDa chondroitin sulfate proteoglycan with a core glycoprotein of 120 kDa were obtained. Immunohistological study revealed that the proteoglycan was associated with developing neurons. We screened rat brain cDNA libraries using the four monoclonal antibodies and isolated overlapping cDNA clones that encoded the entire core protein of 514 amino acids plus a 30-residue signal peptide. The deduced amino acid sequence suggested an integral membrane protein divided into five structurally different domains: an N-terminal domain to which chondroitin sulfate chains might be attached, a basic amino acid cluster consisting of seven arginine and two lysine residues, a cysteine-containing domain, a membrane-spanning segment, and a C-terminal cytoplasmic domain of 95 amino acids. On Northern blots, the cDNA hybridized with a single mRNA of 3.1 kilobases that was detectable in brains of neonatal and adult rats but not in kidney, liver, lung, and muscle of either. The sequence of the proteoglycan did not exhibit significant homology to any other known protein, indicating that the proteoglycan, designated neuroglycan C, is a novel integral membrane proteoglycan.

Aggrecans↗
PubMed1995

Detection of Alzheimer's beta-amyloid precursor related proteins bearing chondroitin sulfate both in the juvenile rat brain and in the conditioned medium of primary cultured astrocytes.

Alzheimer's beta-amyloid precursor related proteins bearing chondroitin sulfate chains were detected in the conditioned media of primary cultured astrocytes obtained from fetal rat brains by Western blotting using the monoclonal antibody 22C11 against Alzheimer's beta-amyloid precursor protein (APP), but not in the media of cortical neurons. The chondroitin sulfate proteoglycan form of APP was also detectable in a soluble proteoglycan fraction prepared from 10-day-old rat brains. However, the amount of proteoglycan form of APP in the brain was very small compared to non-proteoglycan forms at all the developmental stages from embryonic day 14 to 2 years. These observations suggest that astrocytes are one cellular source of the proteoglycan form of APP in the brain.

Alzheimer Disease↗
PubMed1995

Distribution of a brain-specific proteoglycan, neurocan, and the corresponding mRNA during the formation of barrels in the rat somatosensory cortex.

Neurocan is a developmentally regulated chondroitin sulphate proteoglycan in the rat brain. In the present study, spatiotemporal patterns of expression of neurocan and the corresponding mRNA were examined in the developing cortical barrel field of the rat brain by using a monoclonal antibody that was highly specific to neurocan and a riboprobe for a portion of the mRNA. Immunohistochemical analysis revealed that neurocan was distributed throughout the cerebral cortex during early postnatal development but was excluded from the centres of cortical barrels at the time of entry and arborization of thalamocortical axons. At this developmental stage, expression of neurocan mRNA was shown by in situ hybridization to be down-regulated in the barrel centres. When a row of whisker follicles was laser-cauterized on postnatal day 1, the pattern of expression of neurocan was disturbed in the row of barrels that corresponded to the lesioned whisker follicles in the contralateral somatosensory cortex. From these observations, it appears that neuronal stimuli through early thalamocortical fibres from the sensory periphery cause reduced expression of neurocan mRNA in neurocan-producing cells in the presumptive barrel centres. Our findings also suggest that the pattern of distribution of neurocan in early postnatal barrel fields may be due mainly to the down-regulation of expression of neurocan mRNA.

Animals↗
PubMed1995

Chondroitin sulphate proteoglycans in the rat brain: candidates for axon barriers of sensory neurons and the possible modification by laminin of their actions.

The addition of chondroitin sulphate proteoglycans (CSPGs), purified from the rat brain, to the culture medium of PC12D cells inhibited their proliferation and neurite outgrowth. Therefore, we investigated the effects of several extracellular components on the inhibitory actions of CSPGs on PC12D cells, as well as their immunocytochemical distribution in the rat embryo to determine whether the findings in vitro could be reproduced in vivo. Coating of the substratum with polylysine was necessary for the appearance of the inhibitory effects of brain CSPGs on PC12D cells. The additional pretreatment of polylysine-coated dishes with laminin or fibronectin promoted the outgrowth of neurites from PC12D cells. Laminin and fibronectin, but not collagen (types I and IV) and CELL-TAK (cell adhesion molecules), prevented the inhibitory effects of brain CSPGs in a concentration-dependent manner. Doses producing 50% reduction by laminin (or fibronectin) of the CSPG effects were 1.5 (or 25) micrograms/ml for neurite outgrowth and 2.2 (or 28) micrograms/ml for proliferation. The ratio of dish-attached CSPGs to laminin necessary for 50% reduction was about approximately 50:1 (wt/wt). Laminin from any source had the same effect. Brain CSPGs also obviously impeded the growth of fibres from dorsal root ganglion explants and primary cultured dorsal root ganglion neurons. Neurocan (a major CSPG in the brain)-like immunoreactivity was detected in the boundary caps and roof plate in the rat embryo at 13.5 days of gestation, when DRG neurons were extending their axons to the neural tube. The distributions of laminin and tenascin appeared, respectively, to be slightly and considerably different from that of neurocan.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1995

Purification, characterization and developmental expression of a brain-specific chondroitin sulfate proteoglycan, 6B4 proteoglycan/phosphacan.

A large brain-specific chondroitin sulfate proteoglycan, identified with monoclonal antibody 6B4 (6B4 proteoglycan/phosphacan), was isolated from rat brain. Soluble proteoglycans in the phosphate-buffered saline extract from 20-day-old rat whole brain were fractionated by anion exchange chromatography and CsCl density gradient centrifugation. 6B4 proteoglycan was further purified by gel filtration and additional ion exchange chromatography. The molecular mass of 6B4 proteoglycan shifted from 800 to 300 x 10(3) mol. wt after chondroitinase ABC digestion. The core protein was substituted with chondroitin sulfate chains with an average molecular weight of 21,000, keratan sulfate and HNK-1 carbohydrates. Glycosidase digestion of 6B4 proteoglycan with O-glycanase, N-glycanase, endo-beta-galactosidase, or keratanase did not remove the HNK-1 epitopes. The expression of 6B4 proteoglycan was developmentally regulated in the rat cerebral cortex; appearing first at embryonic day 14, peaking at postnatal day 0, and persisting throughout adulthood at a lower level. Immunohistochemical analysis indicated that 6B4 proteoglycan was distributed along the radial glial fibers and on the migrating neurons in the embryonal rar cerebrum. The radial glial fibers were stained intensely all along their length, but the neurons in the cortical plate were not stained in contrast to the moderate staining of the migrating neurons in the intermediate zone and the subplate. From postnatal day 5 to postnatal day 20, 6B4 proteoglycan was present throughout the cortex. After postnatal day 30, staining of the neuropil was weakened, and the expression of 6B4 proteoglycan was restricted around subsets of neurons. The positive neurons were mostly non-pyramidal cells (> 95%) and were relatively concentrated in layers IV and VI of the primary somatosensory cortex. Immunohistochemical analysis of the dissociated cortical neurons indicated that 6B4 proteoglycan was distributed on the cell bodies and neurites. 6B4 proteoglycan strikingly promoted neurite extension of cortical neurons from embryonic day-16 rat embryos when coated on coverslips as a substrate. 6B4 proteoglycan is a brain-specific chondroitin sulfate proteoglycan which carries keratan sulfate and HNK-1 carbohydrates. The spatiotemporal expression profile and effects on the dissociated cerebral neurons suggest that 6B4 proteoglycan plays important roles in the migration and differentiation of neurons in the immature cortex, and also in the maintenance of subsets of neurons in the mature cortex.

Animals↗
PubMed1995

[Proteoglycans in the developing brain].

The occurrence of multiple proteoglycan species is a characteristic of the brain. To identify each proteoglycan molecule, we have raised several monoclonal antibodies against either the soluble or membrane-bound proteoglycan fraction from 10-day-old rat brains. The monoclonal antibody 1G2 recognized neurocan, a soluble chondroitin sulfate proteoglycan (CSPG) unique to the brain. Immunohistological and cell biological results suggested that neurocan regulates neurite outgrowth through specific binding to N-CAM and Ng-CAM at the surface of neurons. In addition, the expression of neurocan was dependent upon neuronal activity evoked by environmental stimuli at least in the developing barrel field. Another CSPG, 6B4-PG, was expressed specifically in the cerebellar mossy fiber system in the rat hindbrain, suggesting that it plays roles in the establishment of this particular neuronal circuit. A membrane-bound heparan sulfate proteoglycan with a 140 kDa core glycoprotein (tentatively designated growth-can) was shown immunohistologically to be transiently expressed in association with growing axons and at the sites of synapse formation. Thus, many neuronal proteoglycans may be involved in various phases of neuronal network formation in the brain. In the near future, progress both in molecular cloning of core proteins and in glycobiology of carbohydrates of proteoglycans will probably produce much experimental evidence to show that neural proteoglycans play pivotal roles during various stages of brain development.

Animals↗
PubMed1995

[Incidence of acute idiopathic optic neuritis and its therapy in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG)].

Data on the incidence of and treatment for acute idiopathic optic neuritis were obtained by questionnaire sent to departments of ophthalmology, university hospitals, and general hospitals throughout Japan. Inquiry was made as to the number of cases which developed idiopathic optic neuritis from April 1992 to March 1993 along with their clinical features. The response rate was 53.6%. There were a total of 550 cases, and the male to female ratio was 1:1.22. Patients 14 to 55 years old were 65.9%; bilateral involvement: 28.2%; recurrence: 18.6%; positive past history of the other eye; 7.5%. Assuming the answering rate to be 100% and two thirds of the patients to be included, annual incidence of this disease (the annual number of patients) was determined to be 1.62 for an adult population of 100,000 (1.03 cases/100,000 people). Tochigi, Tokyo, Kanagawa, Hyogo, Wakayama, Okayama, Yamaguchi, Tottori, Shimane, Ehime, and Fukuoka showed an annual incidence exceeding 2.0/100,000 adults. At more than 95% of all medical institutions questioned, patients with optic neuritis were usually treated with systemic corticosteroids. Oral corticosteroid therapy, which was shown in a recent study in USA to be contraindicated, was still being used at 15% of the institutions.

Acute Disease↗